Project Grant K23AI186597
Award Date
8/20/24
Completion Date
7/31/29
Dollars Obligated
$193K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $209,750 to Emory University to leverage antibody-omics technologies to prevent and detect tuberculosis (TB) in children affected by HIV. The key objectives are to: 1) Define antibody Fc features associated with protection from Mycobacterium tuberculosis (MTB) infection in infants with and without maternal HIV exposure, and 2) Identify...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $817,252 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center (VUMC) to conduct a study entitled "Investigating Multiple PK and PD Relationships for TB-HIV (IMPPROVE TB-HIV)". This 1-year project aims to leverage VUMC's Tuberculosis Sentinel Research Network to perform pharmacokinetic-pharmacodynamic (PK-PD) analyses on first-line...
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize metabolic profiles and outcomes among tuberculosis (TB) patients in Tanzania. The $201,549 award to the Medical University of South Carolina will fund a 5-year study with the following objectives: Measure and describe metabolic markers and TB severity at the time of TB diagnosis, testing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,200 to study the mechanisms of interferon-gamma (IFN-γ)-independent T cell and B cell-mediated protection against tuberculosis (TB) in humans. The research aims to elucidate the IFN-γ-independent T cell response and characterize the B cell, antibody, and T follicular helper (Tfh) cell responses in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the burden, severity, and phenotypic presentation of post-tuberculosis (TB) lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in TB patients with and without HIV. The total funding amount is $743,698.00 over the award period from Sep 20, 2024 to Aug 31, 2029. The grant will leverage an...